Hemophilia B Gene Therapy Demonstrates Long-Term Efficacy and Safety

Hematology Advisor·Jun 16

This story is reported by Hematology Advisor. Read what other outlets are saying below, then open the original report for full details.

Full coverage

1

Single-Dose Gene Therapy Shows Promising Safety, Efficacy, and Patient-Reported Outcomes in Hemophilia B

Docwire News·Mar 11

2

Novo Nordisk's denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026

PR Newswire·Jul 11

3

Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials

Nature·Nov 20

4

New gene therapy reduces bleeding rates for hemophilia B patients

Hemophilia News Today·Dec 23

5

EAHAD 2026: Nine-Year Outcomes of Gene Therapy

EMJ·Feb 6

6

Hemophilia B gene therapy demonstrates long-term success

St. Jude Children's Research Hospital·Jun 11

7

FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial

Applied Clinical Trials Online·Apr 17

8

Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec) Over Five Years

Mynewsdesk·Dec 9